Disrupt Health Impact Fund backs Osteoboost in push to bring FDA-cleared bone-loss wearable to Southeast Asia
What's the deal? Thailand-based Disrupt Health Impact FundDealroom has a profile for this one. Try Dealroom → has invested in Osteoboost, a US women's health-tech startup that makes the first and only FDA-cleared wearable medical device designed to slow bone loss. The device uses precision vibration therapy — inspired by NASA research on astronauts in zero gravity — to target the spine and hip, the areas most vulnerable in postmenopausal women. Clinical trials showed users reduced bone loss by 85% and maintained 83% of bone strength, with no side effects.
The fund and Osteoboost plan to bring the device to Thailand and Southeast Asia as a next step.
Why now? Osteoporosis affects roughly 500 million people worldwide. Among women over 50, the prevalence rate sits at 21.2%, according to the International Osteoporosis Foundation (IOF). Postmenopausal women can lose up to 20% of bone mass within five to seven years — and 75% of hip fracture patients are women, with a first-year mortality rate of 20–24%.
IOF projects that global female hip fractures will rise 240% by 2050 compared with 1990, driven by ageing populations — especially in Asia. Current treatments for the early stage of bone thinning are limited to vitamin D, calcium, and weight-bearing exercise; most drugs are reserved for advanced osteoporosis only. That leaves a wide treatment gap Osteoboost aims to fill.
What could go wrong? The device requires use at least three times a week for 30 minutes per session. Patient compliance with at-home medical devices is notoriously uneven. Expanding into Southeast Asia also means navigating a patchwork of regulatory frameworks — FDA clearance alone won't guarantee swift market entry across the region.
No investment amount was disclosed, making it hard to gauge the scale of Disrupt Health Impact Fund's commitment or how far the capital will stretch for regional expansion.
The signal: Disrupt Health Impact Fund's bet on Osteoboost reflects a growing investor appetite for preventive healthtech that targets the gap between lifestyle advice and heavy pharmaceuticals — a space largely overlooked by venture capital until recently. With Asia's ageing demographics accelerating faster than in any other region, early-stage funds rooted in Southeast Asia are increasingly looking to the US for FDA-validated deep-tech they can localise, rather than waiting for homegrown solutions to mature.
Read more: techsauce.co
